Several factors are associated with increased mortality in patients with bullous pemphigoid, with mortality rates increasing 5 years after diagnosis.

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

An sBLA seeking approval of Dupixent for treating bullous pemphigoid (“BP”) is currently under priority review in the United States. A decision from the FDA is expected on June 20, 2025.

For example, bullous pemphigoid — a type of autoimmune disorder that affects older adults — is typically treated with oral steroids to help reduce inflammation and possibly immunosuppressants ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

Details and references regarding individual diseases are provided in the Supplementary Appendix. CIDP denotes chronic inflammatory demyelinating polyneuropathy, Covid-19 coronavirus disease 2019 ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...